170 related articles for article (PubMed ID: 12177774)
1. Concurrent administration of Docetaxel and Stealth liposomal doxorubicin with radiotherapy in non-small cell lung cancer : excellent tolerance using subcutaneous amifostine for cytoprotection.
Koukourakis MI; Romanidis K; Froudarakis M; Kyrgias G; Koukourakis GV; Retalis G; Bahlitzanakis N
Br J Cancer; 2002 Aug; 87(4):385-92. PubMed ID: 12177774
[TBL] [Abstract][Full Text] [Related]
2. Phase I/II dose escalation study of docetaxel and carboplatin combination supported with amifostine and GM-CSF in patients with incomplete response following docetaxel chemo-radiotherapy: additional chemotherapy enhances regression of residual cancer.
Koukourakis MI; Giatromanolaki A; Kakolyris S; Froudarakis M; Georgoulias V; Retalis G; Bahlitzanakis N
Med Oncol; 2000 May; 17(2):135-43. PubMed ID: 10871820
[TBL] [Abstract][Full Text] [Related]
3. Concurrent twice-a-week docetaxel and radiotherapy: a dose escalation trial with immunological toxicity evaluation.
Koukourakis MI; Giatromanolaki A; Schiza S; Kakolyris S; Georgoulias V
Int J Radiat Oncol Biol Phys; 1999 Jan; 43(1):107-14. PubMed ID: 9989521
[TBL] [Abstract][Full Text] [Related]
4. Thoracic radiotherapy and daily vinorelbine as radiosensitizer in locally advanced non small cell lung cancer: a phase I study.
Gridelli C; Guida C; Barletta E; Gatani T; Fiore F; Barzelloni ML; Rossi A; de Bellis M; D'Aniello R; Scognamiglio F
Lung Cancer; 2000 Aug; 29(2):131-7. PubMed ID: 10963843
[TBL] [Abstract][Full Text] [Related]
5. Effect of amifostine on toxicities associated with sequential chemotherapy and radiation therapy for unresectable non-small-cell lung cancer: results of a phase II trial.
Tannehill SP; Mehta MP; Larson M; Storer B; Pellet J; Kinsella TJ; Schiller JH
J Clin Oncol; 1997 Aug; 15(8):2850-7. PubMed ID: 9256128
[TBL] [Abstract][Full Text] [Related]
6. Triplet chemotherapy with docetaxel, gemcitabine and liposomal doxorubicin, supported with subcutaneous amifostine and hemopoietic growth factors, in advanced non-small cell lung cancer.
Patlakas G; Bouros D; Tsantekidou-Pozova S; Koukourakis MI
Anticancer Res; 2005; 25(2B):1427-31. PubMed ID: 15865101
[TBL] [Abstract][Full Text] [Related]
7. A phase I trial of weekly docetaxel and cisplatinum combined to concurrent hyperfractionated radiotherapy for non-small cell lung cancer and squamous cell carcinoma of head and neck.
Varveris H; Mazonakis M; Vlachaki M; Kachris S; Lyraraki E; Zoras O; Maris T; Froudarakis M; Velegrakis J; Perysinakis C; Damilakis J; Samonis G
Oncol Rep; 2003; 10(1):185-95. PubMed ID: 12469168
[TBL] [Abstract][Full Text] [Related]
8. Concurrent conventionally factionated radiotherapy and weekly docetaxel in the treatment of stage IIIb non-small-cell lung carcinoma.
Koukourakis MI; Bahlitzanakis N; Froudarakis M; Giatromanolaki A; Georgoulias V; Koumiotaki S; Christodoulou M; Kyrias G; Skarlatos J; Kostantelos J; Beroukas K
Br J Cancer; 1999 Aug; 80(11):1792-6. PubMed ID: 10468298
[TBL] [Abstract][Full Text] [Related]
9. Effect of amifostine on toxicities associated with radiochemotherapy in patients with locally advanced non-small-cell lung cancer.
Antonadou D; Throuvalas N; Petridis A; Bolanos N; Sagriotis A; Synodinou M
Int J Radiat Oncol Biol Phys; 2003 Oct; 57(2):402-8. PubMed ID: 12957251
[TBL] [Abstract][Full Text] [Related]
10. Hypofractionated/accelerated radiotherapy with cytoprotection (HypoARC) combined with vinorelbine and liposomal doxorubicin for locally advanced non-small cell lung cancer (NSCLC).
Tsoutsou PG; Froudarakis ME; Bouros D; Koukourakis MI
Anticancer Res; 2008; 28(2B):1349-54. PubMed ID: 18505077
[TBL] [Abstract][Full Text] [Related]
11. Randomized double-blind trial of combined modality treatment with or without amifostine in unresectable stage III non-small-cell lung cancer.
Leong SS; Tan EH; Fong KW; Wilder-Smith E; Ong YK; Tai BC; Chew L; Lim SH; Wee J; Lee KM; Foo KF; Ang P; Ang PT
J Clin Oncol; 2003 May; 21(9):1767-74. PubMed ID: 12721253
[TBL] [Abstract][Full Text] [Related]
12. Reduction of treatment breaks and radiation-induced esophagitis and pneumonitis using amifostine in unresectable non-small cell lung cancer patients receiving definitive concurrent chemotherapy and radiation therapy: a prospective community-based clinical trial.
Wynn RB; Mehta V
Semin Oncol; 2005 Apr; 32(2 Suppl 3):S99-104. PubMed ID: 16015543
[TBL] [Abstract][Full Text] [Related]
13. Docetaxel (Taxotere) in combination with radiation therapy and the potential of weekly administration in elderly and/or poor performance status patients with advanced non-small cell lung cancer.
Hainsworth JD; Vokes EE
Semin Oncol; 2001 Feb; 28(1 Suppl 2):22-7. PubMed ID: 11284621
[TBL] [Abstract][Full Text] [Related]
14. Concomitant weekly docetaxel, cisplatin and radiation therapy in locally advanced non-small cell lung cancer: a dose finding study.
Mudad R; Ramsey M; Kovitz K; Curiel TJ; Hartz R; Nedzi LL; Weiner RS; Zakris EL
Lung Cancer; 2003 Feb; 39(2):173-7. PubMed ID: 12581570
[TBL] [Abstract][Full Text] [Related]
15. Liposomal doxorubicin and conventionally fractionated radiotherapy in the treatment of locally advanced non-small-cell lung cancer and head and neck cancer.
Koukourakis MI; Koukouraki S; Giatromanolaki A; Archimandritis SC; Skarlatos J; Beroukas K; Bizakis JG; Retalis G; Karkavitsas N; Helidonis ES
J Clin Oncol; 1999 Nov; 17(11):3512-21. PubMed ID: 10550149
[TBL] [Abstract][Full Text] [Related]
16. Phase I trial of outpatient weekly docetaxel, carboplatin and concurrent thoracic radiation therapy for stage III unresectable non-small-cell lung cancer: a Vanderbilt cancer center affiliate network (VCCAN) trial.
Choy H; DeVore RF; Hande KR; Porter LL; Rosenblatt PA; Slovis B; Laporte K; Shyr Y; Johnson DH
Lung Cancer; 2001 Dec; 34(3):441-9. PubMed ID: 11714542
[TBL] [Abstract][Full Text] [Related]
17. Randomized phase 2 study of subcutaneous amifostine versus epoetin-alpha given 3 times weekly during concurrent chemotherapy and hyperfractionated radiotherapy for limited-disease small cell lung cancer.
Han HS; Han JY; Yu SY; Pyo HR; Kim HY; Cho KH; Lee DH; Kim HT; Lee JS
Cancer; 2008 Oct; 113(7):1623-31. PubMed ID: 18671241
[TBL] [Abstract][Full Text] [Related]
18. Concurrent two-dimensional radiotherapy and weekly docetaxel in the treatment of stage III non-small cell lung cancer: a good local response but no good survival due to radiation pneumonitis.
Onishi H; Kuriyama K; Yamaguchi M; Komiyama T; Tanaka S; Araki T; Nishikawa K; Ishihara H
Lung Cancer; 2003 Apr; 40(1):79-84. PubMed ID: 12660011
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of weekly docetaxel and cisplatin concurrent with thoracic radiotherapy in Stage III non-small-cell lung cancer.
Wu HG; Bang YJ; Choi EK; Ahn YC; Kim YW; Lim TH; Suh C; Park K; Park CI
Int J Radiat Oncol Biol Phys; 2002 Jan; 52(1):75-80. PubMed ID: 11777624
[TBL] [Abstract][Full Text] [Related]
20. Amifostine reduces radiochemotherapy-induced toxicities in patients with locally advanced non-small cell lung cancer.
Antonadou D; Petridis A; Synodinou M; Throuvalas N; Bolanos N; Veslemes M; Sagriotis A
Semin Oncol; 2003 Dec; 30(6 Suppl 18):2-9. PubMed ID: 14727235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
